Prof. Irwin commented: "Evogene is addressing core challenges in small-molecule discovery through a rigorous and data-driven computational approach. I am pleased to join the Scientific Advisory Board and support the continued advancement of ChemPass AIâ"¢, particularly in ligand discovery, virtual screening, and evidence-based decision-making." Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AIâ"¢ for Drug and Ag-Chemical Discovery REHOVOT, Israel, Feb. 9, 2026 /PRNews ...

Core Insights - Evogene Ltd. and Lishan Biotech have entered into an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic aimed at enhancing anti-tumor immune activity [1] - BMC128 is currently in Phase 1 clinical trials, showing promising early results in renal cell carcinoma and non-small cell lung cancer, with a good safety profile and early signs of efficacy [1] - Lishan Biotech will take over global clinical development, manufacturing, and commercialization of BMC128, while Biomica will receive milestone payments and royalties [1] Company Overview - Evogene Ltd. specializes in computational chemistry and the generative design of small molecules for pharmaceutical and agricultural applications, utilizing its proprietary ChemPass AI™ technology [2] - Lishan Biotech focuses on innovative therapies for complex chronic diseases, employing unique technologies to address unmet medical needs in inflammation, oncology, and neurological disorders [4]

Core Insights - Evogene Ltd. and Lishan Biotech have entered into an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic aimed at enhancing anti-tumor immune activity, which is currently completing Phase 1 clinical studies with promising early results [1][3]. Company Overview - Evogene Ltd. specializes in computational chemistry and generative design of small molecules for pharmaceutical and agricultural industries, utilizing its proprietary ChemPass AI™ technology to improve success rates and reduce development time and costs [5][6]. - Lishan Biotech focuses on innovative therapies for complex chronic diseases, employing unique technologies to address gut microbial colonization and developing microbiome-based therapies for oncology and other conditions [7]. Clinical Development - BMC128 is a live biopharmaceutical consortium composed of four human gut bacterial strains that enhance responses to immunotherapy, currently being studied in renal cell carcinoma and non-small cell lung cancer, showing an excellent safety profile and early signs of efficacy [2][3]. - Under the licensing agreement, Lishan Biotech will manage global clinical development, manufacturing, and commercialization of BMC128, with Biomica eligible for milestone payments and royalties [3]. Future Plans - Lishan Biotech intends to advance BMC128 into Phase 2 clinical studies and pursue regulatory filings in both China and the United States for commercialization [3]. - The collaboration aims to leverage Lishan Biotech's development capabilities and Evogene's innovation in microbiome science to create value in difficult-to-treat cancers [4].

Core Viewpoint - EverGen Infrastructure Corp. has entered into a 20-year Biomethane Purchase Agreement with FortisBC Energy Inc. for the purchase of Renewable Natural Gas produced at its Fraser Valley Biogas facility, marking a significant step in supporting renewable energy initiatives and reducing greenhouse gas emissions [1][2]. Group 1: Agreement Details - The Biomethane Purchase Agreement (BPA) allows FortisBC to purchase Renewable Natural Gas (RNG) from Fraser Valley Biogas Ltd. (FVB) for integration into its natural gas system, which will help reduce reliance on conventional natural gas and lower greenhouse gas emissions [2][3]. - This agreement provides EverGen with a long-term, contracted revenue stream and supports FortisBC's commitment to a renewable and lower carbon gas supply [2][3]. Group 2: Company Background - Fraser Valley Biogas, a wholly owned subsidiary of EverGen, is recognized as the original RNG project in Western Canada and the first to inject RNG into FortisBC's network, utilizing anaerobic digestion and biogas upgrading processes [4]. - The facility not only produces RNG but also generates organic liquid fertilizer from agricultural waste, contributing to sustainable farming practices in the region [4]. Group 3: Company Mission and Growth - EverGen Infrastructure Corp. is positioned as Canada's Renewable Natural Gas Infrastructure Platform, focusing on combating climate change and promoting sustainable energy solutions [5]. - The company is an independent renewable energy producer with plans for continued growth across North America, emphasizing the development and operation of renewable energy projects [5].

Core Viewpoint - EverGen Infrastructure Corp. has successfully closed a $13.0 million asset-level debt facility with Farm Credit Canada, which will support its subsidiary Fraser Valley Biogas Ltd. [1] Financial Developments - The company has repaid the majority of its corporate debt facility, indicating a strengthening financial position [1] - The closing of the second tranche of its previously announced non-brokered private placement is also highlighted, suggesting ongoing capital-raising efforts [1]

Core Viewpoint - EverGen Infrastructure Corp. is advancing its debt refinancing and private placement initiatives, which are expected to strengthen its financial position and support growth in 2026 [2][3]. Debt Refinancing Activities - EverGen has executed a letter of intent for a $13 million asset-level debt facility aimed at repaying a majority of its corporate debt, with terms aligned to its current operations [2]. - The company has entered into a Credit Agreement with Farm Credit Canada for a $13 million term loan and a $250,000 operating line of credit, with closing expected soon [3]. Private Placement Update - The second tranche of a non-brokered private placement is being extended for up to 11,666,667 common shares, aiming for gross proceeds of up to $7 million at a price of $0.60 per share [4]. - The first tranche closed on May 21, 2025, raising $5 million through the issuance of 8,333,333 common shares [4]. - The second tranche is expected to close soon, with proceeds primarily allocated for debt repayment and working capital [5]. Company Overview - EverGen Infrastructure Corp. is a Canadian renewable natural gas infrastructure platform focused on combating climate change and promoting sustainability [6]. - The company operates a portfolio of renewable energy projects and is expected to continue its growth across North America [6].

Core Insights - The partnership between Evogene Ltd. and Unravel Biosciences aims to address the unmet need for remyelination therapies in multiple sclerosis and other demyelinating conditions by leveraging advanced generative chemistry design and predictive platforms [1][2][3] Company Overview - Evogene Ltd. is a pioneering computational chemistry company specializing in the generative design of small molecules for pharmaceutical and agricultural industries [7] - Unravel Biosciences is a clinical-stage therapeutics company focused on advancing drugs for complex diseases through its Predictable Medicine platform [10] Collaboration Details - The collaboration seeks to design and validate brain-penetrant inhibitors targeting a novel demyelination target identified by Unravel's platform, aiming to create the first therapeutic capable of restoring myelin and improving neurological function [3][4] - Evogene's ChemPass AI will be utilized to advance novel drug targets for remyelination, optimizing drug candidates based on insights from Unravel's experimental systems [5][6] Scientific Approach - The partnership combines Evogene's state-of-the-art computational capabilities with Unravel's AI-powered predictive biology platform, utilizing RNA-based simulations and patient data to generate novel therapeutic insights [4][6] - The collaboration emphasizes a function-first discovery approach to gain biological insights from genetically defined demyelinating disorders, facilitating the translation of these insights into therapeutic applications [3][5] Market Need - Degenerative diseases, particularly demyelinating diseases like Multiple Sclerosis, affect hundreds of millions globally, with MS impacting approximately 3 million people [2] - Current therapies primarily focus on slowing disease progression rather than repairing existing damage, highlighting a significant unmet need for effective treatments that can reverse myelin loss [2]

Group 1 - The Annual General and Special Meeting of EverGen Infrastructure Corp. is being held both in person and via video conference [2][4] - The meeting is chaired by the CEO of EverGen, Chase Edgelow, who also introduced the directors and officers present [1][2] - A brief corporate update will follow the formal meeting, with a more comprehensive update planned for the coming weeks [3] Group 2 - The meeting will include a report from the scrutineer on the shareholders present, both in person and by proxy, as well as the results of any ballots or polls [4]

Core Insights - Evogene Ltd. is focusing on computational chemistry and the generative design of small molecules for pharmaceuticals and agriculture, with a strategic emphasis on its AI-driven platform, ChemPass AI [1] Financial Performance - On November 20, 2025, Evogene reported earnings per share of $0.44, exceeding the estimated loss of $0.41 per share [2][5] - The company generated revenue of $312,000, which was below the estimated $650,000, indicating challenges in meeting market expectations [2][5] Valuation Metrics - The price-to-sales ratio is approximately 1.40, indicating that investors are willing to pay $1.40 for every dollar of sales, reflecting confidence in Evogene's potential [3] - The enterprise value to sales ratio stands at about 2.04, showing the company's valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is around -0.78, suggesting difficulties in generating positive cash flow from operations [3] Liquidity and Debt Position - Evogene's debt-to-equity ratio is approximately -3.57, indicating more liabilities than equity [4] - The current ratio is about 1.89, suggesting a relatively healthy liquidity position that allows the company to cover its short-term obligations [4]

Core Insights - EverGen Infrastructure Corp. reported its Q3 2025 financial results, highlighting a record in RNG production and ongoing optimization efforts across its facilities [2][5]. Financial Performance - Revenue for Q3 2025 was CAD 2.81 million, a decrease of 22% from CAD 3.60 million in Q3 2024 [4]. - The net loss increased to CAD 1.11 million in Q3 2025 from CAD 0.47 million in Q3 2024, marking a 134% rise [4][8]. - Adjusted EBITDA for Q3 2025 was CAD 0.47 million, down 52% from CAD 0.98 million in the same period last year [4][9]. - Total assets decreased by 16% to CAD 76.54 million from CAD 91.64 million year-over-year [4]. Operational Highlights - RNG production reached a new quarterly record, with total production of 51,770 gigajoules in Q3 2025, an increase of 27% compared to 40,674 gigajoules in Q3 2024 [4][7]. - The FVB facility set a new monthly RNG production record of over 13,000 gigajoules in September 2025 [3][5]. - Incoming organic feedstock decreased by 40% to 15,310 tonnes compared to 25,555 tonnes in Q3 2024 [4]. Strategic Developments - The PCR RNG Expansion project received regulatory support from Abbotsford City Council in July 2025, marking a key milestone [5][10]. - The company is advancing refinancing efforts, targeting a CAD 13 million debt facility to close in Q4 2025, along with an additional private placement of up to CAD 2 million [11]